Table 1.
Characteristic | N = 2642 |
---|---|
Age (years) | |
Median (range) | 56 (25–77) |
Tumour size (mm) | |
Median (range) | 19 (1.2–130.) |
Nodal status [N (%)] | |
pN0 | 1554 (58.8) |
pN1 | 930 (35.2) |
pN2 | 122 (4.6) |
pN3 | 36 (1.4) |
Therapy [N (%)] | |
Endocrine | 348 (13.0) |
Chemotherapy randomization | 1970 (74.6) |
Out of study | 324 (12.4) |
RS result [N (%)] | |
≤11 | 459 (17.4) |
12–25 | 1544 (58.4) |
> 25 | 550 (20.8) |
Unknown | 89 (3.4) |
Central hormone receptor status, [N (%)] | |
ER positive | 2118 (89.7) |
PR positive | 1751 (74.1) |
ER and/or PR positive | 2202 (93.2) |
ER and PR negative | 57 (2.4) |
Unknown | 160 (6.8) |
Central grade [N (%)] | |
Grade 1 | 134 (5.1) |
Grade 2 | 1636 (61.9) |
Grade 3 | 825 (31.2) |
Unknown | 47 (1.8) |
Median Ki-67 (%) | 15 |
ER oestrogen receptor, PR progesterone receptor, RS recurrence score